Invesco Ltd. Cuts Stock Position in Twist Bioscience Corporation (NASDAQ:TWST)

Invesco Ltd. lowered its holdings in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 5.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,384,229 shares of the company's stock after selling 200,205 shares during the period. Invesco Ltd. owned about 5.65% of Twist Bioscience worth $132,865,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. GAMMA Investing LLC boosted its position in Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after purchasing an additional 303 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in shares of Twist Bioscience by 1.7% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock valued at $1,107,000 after buying an additional 403 shares during the period. Summit Investment Advisors Inc. raised its stake in shares of Twist Bioscience by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company's stock valued at $283,000 after buying an additional 443 shares during the period. Versant Capital Management Inc raised its stake in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after buying an additional 580 shares during the period. Finally, Knights of Columbus Asset Advisors LLC raised its stake in shares of Twist Bioscience by 2.7% in the first quarter. Knights of Columbus Asset Advisors LLC now owns 23,178 shares of the company's stock valued at $910,000 after buying an additional 612 shares during the period.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Evercore ISI set a $46.00 target price on Twist Bioscience in a research note on Monday, August 4th. Cowen restated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. The Goldman Sachs Group lowered their target price on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird lowered their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Finally, Guggenheim restated a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $49.40.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $28.84 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience Corporation has a 52-week low of $24.28 and a 52-week high of $55.33. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -19.89 and a beta of 2.36. The business's fifty day moving average is $34.27 and its 200 day moving average is $37.41.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. The company had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Activity

In other news, COO Patrick John Finn sold 1,877 shares of Twist Bioscience stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $55,840.75. Following the completion of the sale, the chief operating officer owned 240,783 shares in the company, valued at approximately $7,163,294.25. This trade represents a 0.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.76, for a total value of $60,005.28. Following the sale, the chief executive officer owned 645,782 shares of the company's stock, valued at approximately $23,093,164.32. This trade represents a 0.26% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,109 shares of company stock worth $425,962. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.